New hope for advanced cancer: first human trial of GS-0201 begins
NCT ID NCT06167317
First seen May 28, 2026 · Last updated Jun 11, 2026 · Updated 4 times
Summary
This early-phase study tests a new drug called GS-0201, given alone or with another cancer drug (sacituzumab govitecan), in adults with advanced solid tumors that have not responded to other treatments. The main goals are to check safety, find the best dose, and see how the body handles the drug. About 278 participants will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chaim Sheba Medical Center
RECRUITINGTel Litwinsky, 52621, Israel
-
Dana-Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02459, United States
-
NEXT Austin
RECRUITINGAustin, Texas, 78758, United States
-
NEXT Dallas
RECRUITINGIrving, Texas, 75039, United States
-
Rambam Health Care Campus
RECRUITINGHaifa, 31096, Israel
-
Tel Aviv Sourasky Medical Center
RECRUITINGTel Aviv, 6423906, Israel
-
The University of Texas MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.